14.01
+1.05(+8.10%)
Currency In USD
| Previous Close | 12.96 |
| Open | 13.04 |
| Day High | 14.22 |
| Day Low | 12.97 |
| 52-Week High | 19.5 |
| 52-Week Low | 2.21 |
| Volume | 1.28M |
| Average Volume | 1.19M |
| Market Cap | 993.92M |
| PE | -3 |
| EPS | -4.67 |
| Moving Average 50 Days | 11.65 |
| Moving Average 200 Days | 7.67 |
| Change | 1.05 |
If you invested $1000 in Phathom Pharmaceuticals, Inc. (PHAT) since IPO date, it would be worth $569.51 as of October 20, 2025 at a share price of $14.01. Whereas If you bought $1000 worth of Phathom Pharmaceuticals, Inc. (PHAT) shares 5 years ago, it would be worth $367.04 as of October 20, 2025 at a share price of $14.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
GlobeNewswire Inc.
9 hours ago
Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializi
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
GlobeNewswire Inc.
Oct 06, 2025 12:00 PM GMT
Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellenceAppointment strengthens Phathom’s leadership team and ability to execute its growth
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
GlobeNewswire Inc.
Aug 20, 2025 12:00 PM GMT
FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include administrati